ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1522

Remission In Spondyloarthritis :  ASDAS and Basdai Thresholds From a Prospective Real Life Study

Marie Godfrin-Valnet1, Marc Puyraveau2 and Daniel Wendling1, 1Service de Rhumatologie, Minjoz University Hospital, Besancon, France, 2Clinical Methodology Center, CHU, Besançon, France

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: remission

  • Tweet
  • Email
  • Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Remission is the current target of management of chronic rheumatic diseases. Whereas in rheumatoid arthritis remission criteria have been recently proposed, in spondyloarthritis, no activity score allows a clear definition for remission. SpA activity is evaluated with the BASDAI score (Bath Ankylosing Spondylitis Disease Activity Index) and more recently with the ASDAS (Ankylosing Spondylitis Disease Activity Score). Thresholds for the ASAS score have been proposed to classify disease activity (inactive, moderate, active, very active), but no remission threshold was defined.

The aim of this study was to evaluate a threshold for remission in SpA patients.

Methods:

In this prospective study, a questionnaire answering the question: “do you consider the disease in remission at the present time ?” was filled by the patient with Spa (according to ASAS classification criteria)  and the rheumatologist. Data allowing BASDAI, ASDAS-CRP and ASDAS-ESR calculation were collected, and PASS (Patient Acceptable Symptomatic State) was also assessed with a specific question at the same time. Thresholds were defined by building ROC curves for remission according to the patient’s and to the rheumatologist’s opinion.

Results:

One hundred and fifty patients were prospectively included, 67.3 % men, mean age 43.2 ± 11.5 years. HLA-B27 was positive in 84.5 % of the patients; SpA was axial in 81.7 %. Mean CRP was 8.6 ± 13.5 mg/l, and mean ESR 17.4 ± 16 mm/hour. PASS was considered by 56.6% of the patients. For disease activity, 47.3 % of the patients had a BASDAI score less than 4 / 10, and 19.2 % an ASDAS-CRP score less than 1.3 (inactive disease) (19.4 % for the ASDAS-ESR score). The thresholds of activity scores for remission defines by ROC curves are reported in table :

Threshold of activity score (ROC curves)

 

Remission « patient »

N : 41 / 128

Remission « physician »

N : 49 / 143

PASS in case of remission « patient »

N : 41 / 128

ASDAS-CRP

95 % CI

Sensibility %

Spécificity %

≤ 1.6

0.67 – 0.84

62.2

86.3

≤ 1.8

0.82 – 0.94

75.6

91

≤ 2.2

0.82 – 099

93.3

100

ASDAS-ESR

95 % CI

Sensibility %

Spécificity %

≤ 1.7

0.71 – 0,.87

63.9

87

≤ 2

0.76 – 0. 90

75.6

82.2

≤ 2.4

0.76 – 0.9

71.4

81.6

BASDAI

95 % CI

Sensibility %

Spécificity %

≤ 3.6

0.71 – 0.86

75.6

75.9

≤ 3.6

0.81 – 0.93

83.7

79.4

 

≤ 4.1

0.80 – 0.90

75.7

85

Conclusion:

This is the first study tempting to define in a large series of patients in real life a threshold for remission in SpA with an ASDAS –CRP less than 1.6. These results corresponding to the patients reported definition are somewhat different from those endorsed by the ASAS classifying SpA as inactive for a threshold less than 1.3. These differences may be related to different study methods: randomized controlled studies, thresholds evaluated by experts at one hand, and real life situation, thresholds evaluated by the patients at the other hand. However, our results are coherent since the remission threshold is lower than PASS, but raise the question of the definition of remission in SpA.


Disclosure:

M. Godfrin-Valnet,
None;

M. Puyraveau,
None;

D. Wendling,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/remission-in-spondyloarthritis-asdas-and-basdai-thresholds-from-a-prospective-real-life-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology